8-K: Exagen Inc. Reports Strong Q2 2026 Results, Boosts Guidance

Exagen Inc. announced record revenue and test volumes for Q2 2026, alongside a reduced net loss and increased full-year revenue guidance.

Summary

• Exagen Inc. reported its financial results for the second quarter ended June 30, 2026.
• The company achieved record total revenue of $19.9 million, a 16% increase year-over-year.
• Test volume for AVISE CTD grew by 11% compared to the second quarter of 2025.
• The trailing twelve-month average selling price (ASP) for AVISE CTD increased to $446 per test.
• Net loss for the quarter was $3.2 million, a significant reduction from $4.4 million in Q2 2025.
• Adjusted EBITDA loss narrowed to $0.1 million, an improvement from a $1.7 million loss in Q2 2025.
• The company ended the quarter with $24.6 million in cash and cash equivalents.
• Full-year 2026 revenue guidance was increased to $72 million $75 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with the company showing strong revenue growth, improved loss metrics, and increased guidance, indicating a strengthening operational and financial position.

Positives

• Record total revenue of $19.9 million, up 16% year-over-year.
• Increased AVISE CTD test volume by 11% compared to Q2 2025.
• Expanded trailing twelve-month ASP for AVISE CTD to $446, a 4% increase.
• Significantly reduced net loss to $3.2 million from $4.4 million in Q2 2025.
• Narrowed adjusted EBITDA loss to $0.1 million from $1.7 million in Q2 2025.
• Increased full-year 2026 revenue guidance to $72 million $75 million.
• Published a systematic review validating strong real-world AVISE Lupus performance, identifying approximately 25% of SLE patients missed by conventional markers.
• Ended the quarter with approximately $25 million in cash and cash equivalents.

Negatives

• The company still reported a net loss of $3.2 million for the quarter.
• Adjusted EBITDA remained a loss of $0.1 million, though significantly improved.
• Cash and cash equivalents decreased to $24.6 million from $32.2 million at the end of 2025.

Risks

• Delays in reimbursement and coverage decisions from Medicare and third-party payors.
• Interactions with regulatory authorities.
• Delays in ongoing and planned clinical trials.
• Potential effects of inflation and tariffs on margins.
• Changes in laws and regulations related to regulatory requirements.
• Dependence on market acceptance of testing products among rheumatologists, patients, and payors.
• Ability to obtain additional funding.
• Third-party payors not providing adequate coverage and reimbursement.

Future Outlook

The company increased its full-year 2026 revenue guidance to a range of $72 million to $75 million, up from the previous guidance of $70 million to $73 million. Management expressed confidence in improving the growth and operating profile of the business, moving towards sustainable profitability and cash generation.

Management Comments

• "We continue to advance Exagen's unique mission to bring clarity to autoimmune disease, said John Aballi, President and Chief Executive Officer."
• "Second quarter financial results demonstrate the progress we're making in improving the growth and operating profile of our business, putting us within reach of sustainable profitability and cash generation."
• "At the same time, we are building on Exagen's leadership in autoimmune diagnostics through continued investment in clinical evidence generation, pipeline innovation and AI-powered tools that support rheumatology workflows to strengthen our role in rheumatology decision-making."

Industry Context

StockSavvy.ai notes that Exagen's performance aligns with a growing demand for specialized diagnostic solutions in the autoimmune disease sector. The company's focus on improving diagnostic accuracy and providing clinical decision support is a key differentiator in a competitive landscape.

Comparison to Industry Standards

• The reported 16% year-over-year revenue growth for Q2 2026 is strong, particularly for a specialized diagnostics company, though direct public comparables are limited without specific market data.
• The improvement in Adjusted EBITDA loss, narrowing to $0.1 million, indicates progress towards operational efficiency, a common goal for companies in this growth phase.
• The increase in ASP for AVISE CTD suggests successful value-based pricing or increased utilization of higher-value testing components, a positive trend in the diagnostics industry.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance and raised guidance.
• Employees: Continued investment in innovation and growth may lead to job security and opportunities.
• Customers (Healthcare Providers): Improved diagnostic tools and clinical support can enhance patient care.
• Payors: Evidence-based validation of AVISE Lupus performance may support reimbursement decisions.

Next Steps

• Continue investment in clinical evidence generation.
• Pursue pipeline innovation.
• Develop AI-powered tools to support rheumatology workflows.
• Focus on achieving sustainable profitability and cash generation.

Key Dates

Recommendation

The company is showing positive operational improvements and has raised guidance, which is encouraging. However, it is still operating at a net loss and has a significant amount of debt. While the trend is positive, further sustained profitability and cash flow generation are needed to warrant a stronger buy recommendation. A 'hold' reflects the current balance of improving fundamentals against ongoing profitability challenges.

Keywords

autoimmune testing, AVISE CTD, lupus diagnosis, rheumatology, financial results, revenue growth, EBITDA, diagnostic solutions